The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp111
RECENT ADVANCES IN PREDICTION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND CIRRHOSIS: INSIGHTS FROM THE GUT MICROBIOME
Date
May 18, 2024
Explore related products in the following collection:
BACKGROUND AND AIMS: There is conflicting data on the risk of fibrosis and liver-related outcomes in patients with lean MASLD and the role of genetic testing in this population…
INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…